High-tech solutions top the list in the fight against eye disease – Engadget
Posted: July 12, 2017 at 11:48 am
Cataracts are the single leading cause of blindness worldwide, afflicting roughly 42 percent of the global population, including more than 22 million Americans. The disease, which causes cloudy patches to form on the eye's normally clear lens, can require surgery if left untreated. That's why Google's DeepMind AI division has teamed with the UK's National Health Service (NHS) and Moorfields Eye Hospital to train a neural network that will help doctors diagnose early stage cataracts.
The neural network is being trained on a million anonymized optical coherence tomography (OCT) scans (think of a sonogram, but using light instead of sound waves) in the hopes it will eventually be able to supplement human doctors' analyses, increasing both the efficiency and accuracy of individual diagnoses.
"OCT has totally revolutionized the field of ophthalmology. It's an imaging system for translucent structures that utilizes coherent light," Dr. Julie Schallhorn, an assistant professor of ophthalmology at UC San Francisco, said. "It was first described in 1998 and it gives near-cell resolution of the cornea, retina and optic nerve.
"The optic nerve is only about 200 microns thick, but you can see every cell in it. It's given us a much-improved understanding of the pathogenesis of diseases and also their response to treatments." The new iteration of OCT also measures the phase-shift of refracted light, allowing doctors to resolve images down to the capillary level and observe the internal structures in unprecedented detail.
"We're great at correcting refractive errors in the eyes so we can give you good vision far away pretty reliably, or up close pretty reliably," Schallhorn continued. "But the act of shifting focus from distance to near requires different optical powers inside the eye. The way the eye handles this when you're young is through a process called 'accommodation.'" There's a muscle that contracts and changes the shape of the lens to help you focus on close objects. When you get older, even before you typically develop cataracts, the lens will stiffen and reduce the eye's ability to change its shape.
"The lenses that we have been putting in during cataract surgery are not able to mimic that [shapeshifting] ability, so people have to wind up wearing reading glasses," Schallhorn said. There's a lot of work in the field to find solutions for this issue and help restore the eye's accommodation.
There are two front-runners for that: Accommodating lenses, which use the same ciliary muscle to shift focus, and multifocal lenses, which work just like your parents' multifocal reading glasses except that they sit directly on the eye itself. The multifocals have been on the market for about a decade, though their design and construction has been refined over that time.
To ensure the lenses that doctors are implanting are just as accurate as the diseased ones they're removing, surgeons are beginning to use optiwave refractive analysis. Traditionally, doctors relied on measurements taken before the surgery to know how to shape the replacement lenses and combined those with nomograms to estimate how powerful the new lens should be.
The key word there is "estimate." "They especially have problems in patients who have already had refractive surgery like LASIK," Schallhorn explained. The ORA system, however, performs a wavefront measurement of the cornea after the cataract has been removed to help surgeons more accurately pick the right replacement lens for the job.
Corneal inlays are also being used. These devices resemble miniature contact lenses but sit in a pocket on the cornea that's been etched out with a LASIK laser to mimic the process of accommodation and provide a greater depth of focus. They essentially serve the same function as camera apertures. The Kamra lens from AcuFocus and the Raindrop Near Vision Inlay from Revision Optics are the only inlays approved by the FDA for use in the US.
Glaucoma afflicts more than 70 million people annually. This disease causes fluid pressure within the eye to gradually increase, eventually damaging the optic nerve that carries electrical signals from the eye to the brain. Normally, detecting the early stages of glaucoma requires a comprehensive eye exam by a trained medical professional -- folks who are often in short supply in rural and underserved communities. However, the Cambridge Consultants' Viewi headset allows anyone to diagnose the disease -- so long as they have a smartphone and 10 minutes to spare.
The Viewi works much like the Daydream View, wherein the phone provides the processing power for a VR headset shell -- except, of course, that instead of watching 360 degree YouTube videos, the screen displays the flashing light patterns used to test for glaucoma. The results are reportedly good enough to share with you eye doctor and take only about five minutes per eye. Best of all, the procedure costs only about $25, which makes it ideal for use in developing nations.
And while there is no known cure for glaucoma, a team of researchers from Stanford University may soon have one. Last July, the team managed to partially restore the vision of mice suffering from a glaucoma-like condition.
Normally, when light hits your eye, specialized cells in the retina convert that light into electrical signals. These signals are then transmitted via retinal ganglion cells, whose long appendages run along the optic nerve and spread out to various parts of the brain's visual-processing bits. But if the optic nerve or the ganglion cells have been damaged through injury or illness, they stay damaged. They won't just grow back like your olfactory sensory nerve.
However, the Stanford team found that subjecting mice to a few weeks of high-contrast visual stimulation after giving them drugs to reactivate the mTOR pathway, which has been shown to instigate new growth in ganglion cells, resulted in "substantial numbers" of new axons. The results are promising, though the team will need to further boost the rate and scope of axon growth before the technique can be applied to humans.
Researchers from Japan have recently taken this idea of cajoling the retina into healing itself and applied it to age-related macular degeneration cases. AMD primarily affects people aged 60 and over (hence the name). It slowly kills cells in the macula, the part of the eye that processes sharp detail, and causes the central focal point of their field of vision to deteriorate, leaving only the peripheral.
The research team from Kyoto University and the RIKEN Center for Developmental Biology first took a skin sample from a human donor, then converted it into induced pluripotent stem (IPS) cells. These IPS cells are effectively blank slates and can be coerced into redeveloping into any kind of cell you need. By injecting these cells into the back of the patient's eye, they should regrow into retinal cells.
In March of this year, the team implanted a batch of these cells into a Japanese sexagenarian who suffers from AMD in the hope that the stem cells would take hold and halt, if not begin to reverse, the damage to his macula. The team has not yet been able to measure the efficacy of this treatment but, should it work out, the researchers will look into creating a stem-cell bank where patients could immediately obtain IPS cells for their treatment rather than wait months for donor samples to be converted.
And while there isn't a reliable treatment for dry-AMD, wherein fatty protein deposits damage the Bruchs membrane, a potent solution for wet-AMD, which involves blood leaking into the eyeball, has been discovered in a most unlikely place: cancer medication. "Genentech started developing a new drug when an ophthalmologist in Florida just decided to inject the commercially available drug into patients eyes," Schallhorn explained.
"Generally this is not a great idea because sometimes things will go terribly wrong," she continued, "but this worked super-well. It basically stops and reverses the growth of these blood vessels." The only problem is that the drugs don't last, requiring patients to receive injections into their eyeballs every four to eight weeks. Genentech and other pharma companies are working to reformulate the drug -- or at least develop a mechanical "reservoir" -- so it has to be injected only once or twice a year.
Stem-cell treatments like those used in the Kyoto University trial have already proved potentially effective against a wide range of genomic diseases, so why shouldn't it work on the rare genetic condition known as choroideremia? This disease is caused by a single faulty gene and primarily affects young men. Similar to AMD, choroideremia causes light-sensitive cells at the back of the eye to slowly wither and die, resulting in partial to complete blindness.
In April of 2016, a team of researchers from Oxford University performed an experimental surgery on a 24-year-old man suffering from the disease. They first injected a small amount of liquid into the back of the eye to lift a section of the retina away from the interior cellular wall. The team then injected functional copies of the gene into that same cavity, replacing the faulty copies and not only halting the process of cellular death but actually restoring a bit of the patient's vision.
Gene therapy may be "surely the most efficient way of treating a disease," lead author of the study, Oxford professor Robert MacLaren, told BBC News, but its widespread use is still a number of years away. Until then, good old-fashioned gadgetry will have to suffice. Take the Argus II, for example.
The Argus II bionic eye from Second Sight has been in circulation since 2013, when the FDA approved its use in treating retinitis pigmentosa. It has since gotten the go-ahead for use with AMD in 2015. The system leverages a wireless implant which sits on the retina and receives image data from an external camera that's mounted on a pair of glasses. The implant converts that data into an electrical signal which stimulates the remaining retinal cells to generate a visual image.
The Argus isn't the only implantable eyepiece. French startup Pixium Vision developed a similar system, the IRIS II, back in 2015 and implanted it in a person last November after receiving clearance from the European Union. The company is already in talks with the FDA to bring its IRIS II successor, a miniaturized wireless subretinal photovoltaic implant called PRIMA, to US clinical trials by the end of this year.
Ultimately, the goal is to be able to replace a damaged or diseased eye entirely, if necessary, using a robotic prosthetic. However, there are still a number of technological hurdles that must be overcome before that happens, as Schallhorn explained.
"The big thing that's holding us back from a fully functional artificial eye is that we need to find a way to interface with the optic nerve and the brain in a way that we transmit signals," she said. "That's the same problem we're facing with prosthetic limbs right now. But there are a lot of smart people in the field working on that, and I'm sure they'll come up with something soon."
Read more:
High-tech solutions top the list in the fight against eye disease - Engadget
- A #ReUp of 2019: The year when gene therapy, DNA modifications came of age & saved lives - Economic Times - December 6th, 2019
- Buyer beware of this $1 million gene therapy for aging - MIT Technology Review - December 6th, 2019
- Patient Turned Advocate Raises Awareness for the Lung Cancer Community - Curetoday.com - December 1st, 2019
- Are we any closer to a cure? - Deccan Herald - December 1st, 2019
- Rheumatoid Arthritis Will Change Your Life. It Doesn't Have to Ruin It. - HealthCentral.com - December 1st, 2019
- San Antonio woman, a singer and dancer with Taylor Swift, gives back to communitys performing arts - San Antonio Express-News - December 1st, 2019
- This Mom Is Buying Mutant Mice From China To Find A Cure For Her Sons Rare Genetic Disease - BuzzFeed News - November 21st, 2019
- Greek-American Doctor's Research Tackles the Tough Armor of Pancreatic Cancer - Hellenic News of America - November 21st, 2019
- Longtime Lung Cancer Thrivers - Curetoday.com - November 18th, 2019
- Mother suing NHS trust after doctors failed to reveal Huntington's disease risk - inews - November 18th, 2019
- Hip osteoarthritis: 6 ways to treat it - Medical News Today - November 18th, 2019
- Ocugen Stock Is Nothing More than a Risky Trade on Even-riskier Biotech - Investorplace.com - November 18th, 2019
- FDA halts trial of Duchenne gene therapy treatment from Solid Biosciences - The Boston Globe - November 13th, 2019
- Solid's Duchenne gene therapy trial halted after patient suffers toxicity - STAT - November 13th, 2019
- Her daughter may die by age 10, but this mom keeps fighting to cure her rare disease - ABC News - November 13th, 2019
- Behind the Scenes of a Radical New Cancer Cure - Scientific American - November 9th, 2019
- Genentech's Gazyva (obinutuzumab), in Combination With Standard of Care, More Than Doubles the Percentage of Lupus Nephritis Patients Achieving... - November 9th, 2019
- Protecting your sight: What you need to know - WNDU-TV - November 8th, 2019
- Researching the Future of Cancer Treatment - Southern Newsroom - November 8th, 2019
- Physician Goes Behind The Scenes To Write Compelling Story About Treating Patients With New Cancer Gene Therapy - Kaiser Health News - November 6th, 2019
- Humanigen"s abstracts on lenzilumab to be presented at the American Society of Hematology - Proactive Investors USA & Canada - November 6th, 2019
- New data to be presented at ASH 2019 highlight Sanofi's commitment to treat challenging blood cancers and rare blood disorders - PRNewswire - November 6th, 2019
- Boy, 2, first in Nebraska to receive $2.1 million therapy for rare disorder. 'He's doing fantastic' - Kearney Hub - November 1st, 2019
- Genome Sequencing In NICU Can Speed Diagnosis Of Rare Inherited Diseases : Shots - Health News - NPR - November 1st, 2019
- Viewpoint: Netflix's new horror movie 'Eli' is a fright. But why did they have to 'tarnish gene therapy'? - Genetic Literacy Project - November 1st, 2019
- From One to Many: The Growing Treatment Landscape of HER2-Positive Breast Cancer - Curetoday.com - November 1st, 2019
- Dr Batra's have launched a new genetics-based therapy that predicts future diseases - Gulf Today - November 1st, 2019
- Dr. April Spencer's ABC's Of Breast Cancer Prevention - Essence - November 1st, 2019
- Every Woman in My Family Had Breast Cancer & None of Us Have the BRCA Gene Mutation - SheKnows - November 1st, 2019
- The 9 Biggest Technology Trends That Will Transform Medicine And Healthcare In 2020 - Forbes - November 1st, 2019
- Community awareness and a local family's strength - Leadercourier-times.com - November 1st, 2019
- Boy, 2, first in Nebraska to receive $2.1 million therapy for rare disorder. 'He's doing fantastic' - Omaha World-Herald - October 27th, 2019
- Every Woman in My Family Had Breast Cancer and None of Us Have the BRCA Gene - STYLECASTER - October 27th, 2019
- CF Patients Voice Hopes and Expectations for Trikafta in Instagram Poll - Cystic Fibrosis News Today - October 27th, 2019
- She reversed her MCI, and here's how she did it - GoCogno.com - October 27th, 2019
- The CAR-T Revolution Is ... Messy - Undark Magazine - October 24th, 2019
- Breast Cancer in Men | Outlook - Big Bear Grizzly - October 24th, 2019
- 5 Biotech and Pharmaceutical Innovation Trends in 2019 - BioSpace - October 23rd, 2019
- Why Are More Black Women Dying From the Most Common Reproductive Cancer? - Mother Jones - October 22nd, 2019
- Genentech's Tecentriq in Combination With Avastin Increased Overall Survival and Progression-free Survival in People With Unresectable Hepatocellular... - October 22nd, 2019
- $2.1 million drug approved for Pearland toddler with rare genetic disease - KHOU.com - October 19th, 2019
- The 'Magic' Behind Every Successful Blockbuster Drug - DailyWealth - October 19th, 2019
- Save your child from paediatric cancer: Know what to look out for - TheHealthSite - October 19th, 2019
- Gene-Therapy Treatment Could Help People with Macular Degeneration - Healthline - October 18th, 2019
- A Netflix Series Explores the Brave New World of Crispr - WIRED - October 18th, 2019
- Pearland family fighting to get $2.1 million drug for toddler with rare genetic disease - KHOU.com - October 18th, 2019
- Daughter drew inspiration from mom in battle with breast cancer, stresses early detection - Gainesville Daily Register - October 18th, 2019
- Cleft palate or lip is one of the most common birth defects worldwide, but do you know what it is? - ABC News - October 18th, 2019
- Deepak Chopra Has Never Been Sick - The New Yorker - October 18th, 2019
- Quebec to cover revolutionary cancer treatment for types of leukemia and non-Hodgkins lymphoma - CTV News - October 11th, 2019
- John Geyman on the Failure of Obamacare the Medical Industrial Complex and the Single Payer Solution - Corporate Crime Reporter - October 11th, 2019
- Metastatic Breast Cancer: What You Should Know - University of Michigan Health System News - October 11th, 2019
- The facts about breast cancer awareness | News - The Albany Herald - October 8th, 2019
- What one doctor thinks about drug shortages and how to solve them - STAT - October 4th, 2019
- Beyoncs father diagnosed with breast cancer - Houston Chronicle - October 4th, 2019
- Study Measures Prognosis for Breast Cancer Patients with High 21-gene Recurrence Score Receiving Adjuvant Chemotherapy Plus Endocrine Therapy -... - October 4th, 2019
- Beyonc's father Mathew Knowles has breast cancer: Here's what you need to know about the disease in men - Yahoo Lifestyle - October 4th, 2019
- Genentech to Present Results of First Prospective Trial Using Blood-based Next Generation Sequencing Which Successfully Identifies People for... - October 2nd, 2019
- Nearly Half of Poland's SMA Patients on Track to Get Spinraza, Experts Say - SMA News Today - September 30th, 2019
- Three to be honored as Distinguished Clay High School Alumni - Press Publications Inc. - September 30th, 2019
- Pollard and Norris in the race for Pos. 2 of the Public Hospital District 4 - Snoqualmie Valley Record - September 30th, 2019
- Gene therapy drug priced at $2 million saves North Carolina babys life - WTKR News 3 - September 26th, 2019
- Here's What Happened to Dr. Sharpe on 'New Amsterdam' Details! - Distractify - September 26th, 2019
- Why the focus of autism research is shifting away from searching for a 'cure' - NBCNews.com - September 26th, 2019
- Targeted Therapy | Treating Mesothelioma - Mesothelioma Hub - September 26th, 2019
- A Study to Evaluate the Efficacy and Safety of Factor IX ... - May 26th, 2019
- Xconomy: SMA Moment: Will Gene Therapy Shift Treatment ... - May 2nd, 2019
- Gene therapy might be a cure for "bubble boy disease ... - April 24th, 2019
- Gene Therapy Questions | FAQs - Dana-Farber/Boston ... - April 22nd, 2019
- Gene Therapy: The Future of Vision Treatment - February 21st, 2019
- Oncotype DX: Genomic Test to Inform Breast Cancer Treatment - September 29th, 2018
- what is gene therapy? - Bluebird Bio - May 24th, 2018
- Gene therapy - Doctor.ndtv.com - May 18th, 2018
- South Bend man a 'walking miracle' after cancer treatment breakthrough - South Bend Tribune - September 6th, 2017
- UTSA Presidential Lecture featuring Leonard Pinchuk - UTSA Today - September 6th, 2017
- Why the federal government urgently needs to fund more cancer research - Los Angeles Times - September 6th, 2017
- New 'hit-and-run' gene editing tool temporarily rewrites genetics to treat cancer and HIV - GeekWire - September 6th, 2017
- First gene therapy to treat cancer gets FDA approval; UM only Michigan hospital to use it - Detroit Free Press - September 1st, 2017
- Man describes new FDA-approved gene therapy for leukemia that changed his life - fox4kc.com - September 1st, 2017
- Gilead is buying Kite Pharma, a cancer-fighting Santa Monica biotech firm, for $11.9 billion - Los Angeles Times - August 30th, 2017